Andrew Peter Sandham
Vorsitzender bei Polyprox Therapeutics Ltd.
Profil
Andrew Peter Sandham founded Cantab Pharmaceuticals Plc, Signature BioScience, Inc., Hexagen Plc, and Ionix Pharmaceuticals Ltd.
Mr. Sandham also currently works at Predictimmune Ltd., as Chairman, Polyprox Therapeutics Ltd., as Executive Chairman from 2019, and Loqus23 Therapeutics Ltd., as Director from 2019.
Mr. Sandham also formerly worked at Kymab Ltd., as Chairman & Chief Executive Officer, Novacta Biosystems Ltd., as Chairman, NeurAxon, Inc., as Chairman, Bicycle Therapeutics Plc, as Chairman from 2011 to 2016, Ipsen Bioinnovation Ltd., as Chairman from 2010 to 2011, Synosia Therapeutics AG, as Director, Plant Bioscience Ltd., as Non-Executive Director, Celltech Group Plc, as Principal, GE Healthcare Ltd.
(United Kingdom), as Principal, Abingworth Management, Inc., as Venture Partner, Roche Ltd., as Principal, and Syncona Partners LLP, as Partner from 2013 to 2015.
Mr. Sandham received his undergraduate degree from Norwich University, undergraduate degree from the University of East Anglia, and graduate degree from Chartered Institute of Personnel & Development.
Aktive Positionen von Andrew Peter Sandham
Unternehmen | Position | Beginn |
---|---|---|
Polyprox Therapeutics Ltd.
Polyprox Therapeutics Ltd. BiotechnologyHealth Technology Polyprox Therapeutics Ltd. operates as biotechnology company which engages in research and development of drugs to treat cancer and neurodegenerative diseases. The company was founded by Laura S. Itzhaki in 2018 and is headquartered in Cambridge, the United Kingdom. | Vorsitzender | 01.03.2019 |
Predictimmune Ltd.
Predictimmune Ltd. Medical SpecialtiesHealth Technology Predictimmune Ltd. develops tools for guiding treatment options in immune-mediated inflammatory diseases. It offers PredictSURE IBD is a biomarker test, combined with a sophisticated, proprietary algorithm that will tell the likely course of newly diagnosed patients’ IBD, differentiating between an aggressive or milder form of the disease. The company was founded in May 2017 and is headquartered in Cambridge, the United Kingdom. | Vorsitzender | - |
Loqus23 Therapeutics Ltd.
Loqus23 Therapeutics Ltd. BiotechnologyHealth Technology Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom. | Direktor/Vorstandsmitglied | 05.09.2019 |
Ehemalige bekannte Positionen von Andrew Peter Sandham
Unternehmen | Position | Ende |
---|---|---|
BICYCLE THERAPEUTICS PLC | Vorsitzender | 18.07.2016 |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Corporate Officer/Principal | 01.12.2015 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Vorstandsvorsitzender | 02.09.2013 |
Ipsen Bioinnovation Ltd.
Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. | Vorsitzender | 06.01.2011 |
Plant Bioscience Ltd.
Plant Bioscience Ltd. Miscellaneous Commercial ServicesCommercial Services Plant Bioscience Ltd. operates as an independent technology management company. The firm specializes in plant, food and microbial science. Its services include identification of opportunities, enhancement and protection of technology, commercialization strategy and business development. The company was founded in 1994 and is headquartered in Norwich, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Ausbildung von Andrew Peter Sandham
Norwich University | Undergraduate Degree |
University of East Anglia | Undergraduate Degree |
Chartered Institute of Personnel & Development | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BICYCLE THERAPEUTICS PLC | Health Technology |
Private Unternehmen | 18 |
---|---|
Cantab Pharmaceuticals Plc
Cantab Pharmaceuticals Plc MiscellaneousMiscellaneous Cantab Pharmaceuticals plc, based in Cambridge, England, was established in 1989 to exploit advances in immunology. Since that time, Cantab has become a leader in the areas of immunotherapy and gene delivery and has developed a broad portfolio of novel products for the treatment and prevention of many chronic infectious diseases, cancer and substance addiction. | Miscellaneous |
Celltech Group Plc
Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Signature BioScience, Inc.
Signature BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services Signature BioScience, Inc. discovers new drugs by applying its parallel target and compound selection process. The private company is based in Hayward, CA and has subsidiaries in the United States. The company was founded by Andrew Peter Sandham and John Hefti. | Commercial Services |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |
Hexagen Plc
Hexagen Plc BiotechnologyHealth Technology Part of Incyte Corp., Hexagen Plc develops technology for the discovery of single nucleotide polymorphisms. The British company was founded by Andrew Peter Sandham, Stephen William Bunting. Hexagen was acquired by Incyte Corp. on September 22, 1998 for $25.99 million. | Health Technology |
Ionix Pharmaceuticals Ltd.
Ionix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Ionix Pharmaceuticals Ltd. used to develop analgesic medicines for the treatment of acute and chronic pain. Its drugs were used for the treatment of pain associated with chronic debilitating diseases such as osteoarthritis, diabetes, cancer and multiple sclerosis. The company was founded by Andrew Sandham, Phillip J. Birch, John Wood and Ann Gail Hayes in 2001 and was located in Cambridge, UK. | Health Technology |
GE Healthcare Ltd. (United Kingdom)
GE Healthcare Ltd. (United Kingdom) Medical SpecialtiesHealth Technology GE Healthcare Ltd. provides transformational medical technologies and services which include icenter, AssetPlus, preventive maintenance, continuity, digital solutions and Unisys multi brand probe repair services. The firm offers magnetic resonance imaging, hemodynamic recording, EP recording, metabolic health and computed tomography. The company was founded on February 16, 1971 and is headquartered in Little Chalfont, the United Kingdom. | Health Technology |
Abingworth Management, Inc.
Abingworth Management, Inc. Investment ManagersFinance Abingworth Management, Inc. invests in life sciences and biomedical companies. The firm's investment in enables technologies, devices and instrumentation as well as companies developing products in therapeutic areas. The company was founded in 1973 and is headquartered in Menlo Park, CA. | Finance |
Roche Ltd.
Roche Ltd. Financial ConglomeratesFinance Roche Ltd. provides investment services. | Finance |
Novacta Biosystems Ltd.
Novacta Biosystems Ltd. BiotechnologyHealth Technology Novacta Biosystems Ltd. discovered and developed drugs for treatment of bacterial infections. Its products included lantibiotic/bacteriocin variants, as well as a development candidate for the treatment of C. difficile infection. The company was founded by John Michael Dawson on February 14, 2015 and was headquartered in London, the United Kingdom. | Health Technology |
NeurAxon, Inc.
NeurAxon, Inc. Miscellaneous Commercial ServicesCommercial Services NeurAxon, Inc. is engaged in the research and development of growing and unmet needs for chronic pain management. It is focused on developing pain therapeutics targeting neuronal Nitric Oxide Synthase (nNOS) inhibitors. The companyw as founded in 2004 and is headquartered in Mississauga, ON. | Commercial Services |
Plant Bioscience Ltd.
Plant Bioscience Ltd. Miscellaneous Commercial ServicesCommercial Services Plant Bioscience Ltd. operates as an independent technology management company. The firm specializes in plant, food and microbial science. Its services include identification of opportunities, enhancement and protection of technology, commercialization strategy and business development. The company was founded in 1994 and is headquartered in Norwich, the United Kingdom. | Commercial Services |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
Ipsen Bioinnovation Ltd.
Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Predictimmune Ltd.
Predictimmune Ltd. Medical SpecialtiesHealth Technology Predictimmune Ltd. develops tools for guiding treatment options in immune-mediated inflammatory diseases. It offers PredictSURE IBD is a biomarker test, combined with a sophisticated, proprietary algorithm that will tell the likely course of newly diagnosed patients’ IBD, differentiating between an aggressive or milder form of the disease. The company was founded in May 2017 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Polyprox Therapeutics Ltd.
Polyprox Therapeutics Ltd. BiotechnologyHealth Technology Polyprox Therapeutics Ltd. operates as biotechnology company which engages in research and development of drugs to treat cancer and neurodegenerative diseases. The company was founded by Laura S. Itzhaki in 2018 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Loqus23 Therapeutics Ltd.
Loqus23 Therapeutics Ltd. BiotechnologyHealth Technology Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom. | Health Technology |